{"title":"鞣酸-铜复合物的合成与表征:一种前景广阔的抗胆碱酯酶药物","authors":"","doi":"10.1016/j.poly.2024.117213","DOIUrl":null,"url":null,"abstract":"<div><p>This study aimed to present an optimized synthetic pathway for a complex formed between copper (II) metal ion and tannic acid (TA), which have a variety of pharmacological properties. The study also focused on characterizing this metallodrug, carrying out <em>in vitro</em> antioxidant and acetylcholinesterase enzyme (AChE) inhibition assays, and performing <em>in vivo</em> toxicity assay against zebrafish (<em>Danio rerio</em>), thus expanding the area of study involving syntheses of metal complexes to act as therapeutic agents. Through various characterization techniques, including UV–Vis Absorption Spectroscopy, Fourier Transform Infrared Spectroscopy (FTIR), Thermal Analysis (TG and DTG), <sup>1</sup>H Nuclear Magnetic Resonance (<sup>1</sup>H NMR), Inductively Coupled Plasma with Optical Emission Spectrometry (ICP-OES), and Electron Paramagnetic Resonance (EPR), it was confirmed that the metal ion is coordinated to the ligand, exhibiting distorted planar square geometry with mononuclear copper (3.10 ± 0.10 % copper by ICP-OES). <em>In vitro</em> tests demonstrated that the TA–Cu complex presents antioxidant activity against DPPH (IC<sub>50</sub> = 2.26 ± 0.01 µg mL<sup>−1</sup>) and ABTS (IC<sub>50</sub> = 1.91 ± 0.07 µg mL<sup>−1</sup>) radical scavenging assays. These results were more promising than those obtained for the TA (4.25 ± 0.03 µg mL<sup>−1</sup> and 3.37 ± 0.03 µg mL<sup>−1</sup>, respectively). In the <em>in vitro</em> inhibition of AChE assay, the TA–Cu complex (4.07 ± 0.04 µg mL<sup>−1</sup>) presented a lower IC<sub>50</sub> value than TA (5.80 ± 0.09 µg mL<sup>−1</sup>), indicating that coordination to the metal center Cu (II) was able to improve the anticholinesterase activity of the free ligand. Furthermore, the TA–Cu complex did not show toxicity in the <em>in vivo</em> test with adult zebrafish for 96 h at the tested doses of 4–40 mg kg<sup>−1</sup>, with LD<sub>50</sub> >40 mg kg<sup>−1</sup>. Thus, it is estimated that the TA–Cu complex is a metallodrug with anticholinesterase potential, representing a promising strategy for conducting future pre-clinical studies in models of Alzheimer’s disease.</p></div>","PeriodicalId":20278,"journal":{"name":"Polyhedron","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Synthesis and characterization of tannic acid–copper complex: A promising anticholinesterase drug\",\"authors\":\"\",\"doi\":\"10.1016/j.poly.2024.117213\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This study aimed to present an optimized synthetic pathway for a complex formed between copper (II) metal ion and tannic acid (TA), which have a variety of pharmacological properties. The study also focused on characterizing this metallodrug, carrying out <em>in vitro</em> antioxidant and acetylcholinesterase enzyme (AChE) inhibition assays, and performing <em>in vivo</em> toxicity assay against zebrafish (<em>Danio rerio</em>), thus expanding the area of study involving syntheses of metal complexes to act as therapeutic agents. Through various characterization techniques, including UV–Vis Absorption Spectroscopy, Fourier Transform Infrared Spectroscopy (FTIR), Thermal Analysis (TG and DTG), <sup>1</sup>H Nuclear Magnetic Resonance (<sup>1</sup>H NMR), Inductively Coupled Plasma with Optical Emission Spectrometry (ICP-OES), and Electron Paramagnetic Resonance (EPR), it was confirmed that the metal ion is coordinated to the ligand, exhibiting distorted planar square geometry with mononuclear copper (3.10 ± 0.10 % copper by ICP-OES). <em>In vitro</em> tests demonstrated that the TA–Cu complex presents antioxidant activity against DPPH (IC<sub>50</sub> = 2.26 ± 0.01 µg mL<sup>−1</sup>) and ABTS (IC<sub>50</sub> = 1.91 ± 0.07 µg mL<sup>−1</sup>) radical scavenging assays. These results were more promising than those obtained for the TA (4.25 ± 0.03 µg mL<sup>−1</sup> and 3.37 ± 0.03 µg mL<sup>−1</sup>, respectively). In the <em>in vitro</em> inhibition of AChE assay, the TA–Cu complex (4.07 ± 0.04 µg mL<sup>−1</sup>) presented a lower IC<sub>50</sub> value than TA (5.80 ± 0.09 µg mL<sup>−1</sup>), indicating that coordination to the metal center Cu (II) was able to improve the anticholinesterase activity of the free ligand. Furthermore, the TA–Cu complex did not show toxicity in the <em>in vivo</em> test with adult zebrafish for 96 h at the tested doses of 4–40 mg kg<sup>−1</sup>, with LD<sub>50</sub> >40 mg kg<sup>−1</sup>. Thus, it is estimated that the TA–Cu complex is a metallodrug with anticholinesterase potential, representing a promising strategy for conducting future pre-clinical studies in models of Alzheimer’s disease.</p></div>\",\"PeriodicalId\":20278,\"journal\":{\"name\":\"Polyhedron\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Polyhedron\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0277538724003899\",\"RegionNum\":3,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, INORGANIC & NUCLEAR\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Polyhedron","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0277538724003899","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}
Synthesis and characterization of tannic acid–copper complex: A promising anticholinesterase drug
This study aimed to present an optimized synthetic pathway for a complex formed between copper (II) metal ion and tannic acid (TA), which have a variety of pharmacological properties. The study also focused on characterizing this metallodrug, carrying out in vitro antioxidant and acetylcholinesterase enzyme (AChE) inhibition assays, and performing in vivo toxicity assay against zebrafish (Danio rerio), thus expanding the area of study involving syntheses of metal complexes to act as therapeutic agents. Through various characterization techniques, including UV–Vis Absorption Spectroscopy, Fourier Transform Infrared Spectroscopy (FTIR), Thermal Analysis (TG and DTG), 1H Nuclear Magnetic Resonance (1H NMR), Inductively Coupled Plasma with Optical Emission Spectrometry (ICP-OES), and Electron Paramagnetic Resonance (EPR), it was confirmed that the metal ion is coordinated to the ligand, exhibiting distorted planar square geometry with mononuclear copper (3.10 ± 0.10 % copper by ICP-OES). In vitro tests demonstrated that the TA–Cu complex presents antioxidant activity against DPPH (IC50 = 2.26 ± 0.01 µg mL−1) and ABTS (IC50 = 1.91 ± 0.07 µg mL−1) radical scavenging assays. These results were more promising than those obtained for the TA (4.25 ± 0.03 µg mL−1 and 3.37 ± 0.03 µg mL−1, respectively). In the in vitro inhibition of AChE assay, the TA–Cu complex (4.07 ± 0.04 µg mL−1) presented a lower IC50 value than TA (5.80 ± 0.09 µg mL−1), indicating that coordination to the metal center Cu (II) was able to improve the anticholinesterase activity of the free ligand. Furthermore, the TA–Cu complex did not show toxicity in the in vivo test with adult zebrafish for 96 h at the tested doses of 4–40 mg kg−1, with LD50 >40 mg kg−1. Thus, it is estimated that the TA–Cu complex is a metallodrug with anticholinesterase potential, representing a promising strategy for conducting future pre-clinical studies in models of Alzheimer’s disease.
期刊介绍:
Polyhedron publishes original, fundamental, experimental and theoretical work of the highest quality in all the major areas of inorganic chemistry. This includes synthetic chemistry, coordination chemistry, organometallic chemistry, bioinorganic chemistry, and solid-state and materials chemistry.
Papers should be significant pieces of work, and all new compounds must be appropriately characterized. The inclusion of single-crystal X-ray structural data is strongly encouraged, but papers reporting only the X-ray structure determination of a single compound will usually not be considered. Papers on solid-state or materials chemistry will be expected to have a significant molecular chemistry component (such as the synthesis and characterization of the molecular precursors and/or a systematic study of the use of different precursors or reaction conditions) or demonstrate a cutting-edge application (for example inorganic materials for energy applications). Papers dealing only with stability constants are not considered.